This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Invitrogen/Life Technologies (C): The "Best Owner" of the Asset
Burgelman, R; Siegel, R; Lee, RCase SGSB-SM209C-EStrategyThis short case discusses the process of Life Technologies’ acquisition by Thermo Fisher in 2013 and 2014. The case is a complement to SM-209A and SM-209B, which highlight the various growth and acquisition strategies the company undertook over the previous 10 years.Starting at €5.74
-
Basware in 2013: Transistion to Software as a Service
Burgelman, R; Schifrin, DCase SGSB-SM219-EStrategyIn 2013 Basware, the Finland-based e-invoice operator and Enterprise Resource Planning (ERP) software vendor, was going through a large and critical transition: moving from selling and installing licensed software to selling Software as a Service (SaaS). Basware, which sold automated Purchase-to-Pay solutions for Business-to-Business to 2,000 Nordic and global clients, was responding to a sharp decline in those sales in the previous few years; mo...Starting at €8.20
-
Axel Springer in 2016: From Transformation to Acceleration - Teaching Note
Burgelman, R; Siegel, R; Kissick, RTeaching Note SGSB-E610TN-EEntrepreneurshipAs of 2016, Mathias Döpfner, chief executive officer (CEO) of Axel Springer SE, had successfully transitioned the German publishing house through a major digital transformation in the world of journalism. Given the massive disruption that had occurred over the previous two decades with how people consumed news, this was no small feat. During this time, many newspapers, magazines, and journals failed to keep up with the rapidly changing industry...Starting at €0.00
-
Axel Springer in 2016: From Transformation to Acceleration
Burgelman, R; Siegel, R; Kissick, RCase SGSB-E610-EEntrepreneurshipAs of 2016, Mathias Döpfner, chief executive officer (CEO) of Axel Springer SE, had successfully transitioned the German publishing house through a major digital transformation in the world of journalism. Given the massive disruption that had occurred over the previous two decades with how people consumed news, this was no small feat. During this time, many newspapers, magazines, and journals failed to keep up with the rapidly changing industry...Starting at €8.20
-
Invitrogen (A)
Burgelman, R; Siegel, R; Lee, RCase SGSB-SM209A-EStrategyFounded in 1987, Invitrogen was one of the largest catalog life science companies in the industry. Its customers came from academic research, biotechnology and pharmaceutical companies and government laboratories. Scientists viewed Invitrogen as a one-stop shop for all major molecular biology, biochemistry and cell culture reagent products, with prices ranging from a hundred dollars to a few thousand dollars.Starting at €8.20
-
Fairview Capital
Rogers, Steven S.; Collins, DerrickCase HBS-319050-EEntrepreneurshipFairview Capital is a pioneering alternative assets investment manager, as it is the first U.S. private equity fund of funds that focused on investing in private equity and venture capital funds managed by African-Americans and other minority investment managers. This case study focuses on Fairview's strategic decisions that ultimately led to the growth and expansion of its investment portfolio to over $3 billion.Starting at €8.20
-
-
-
Earl Gordon - Eastern Circle
Rogers, Steven S.; White, GregCase HBS-317061-EEntrepreneurshipThis case follows an African-American entrepreneur through the process of sourcing a potential acquisition, valuing a company, and securing the funding to purchase the company. This entrepreneur must decide if he should close the deal and which financing term sheet to accept.Starting at €8.20
-
Invitrogen/Life Technologies (B)
Burgelman, R; Siegel, R; Lee, RCase SGSB-SM209B-EStrategyOn June 12, 2008, Invitrogen and Applied Biosystems announced plans to merge. The combined company was to be renamed Life Technologies (NASDAQ: LIFE). Invitrogen offered to acquire Applied Biosystems for $6.7 billion in cash and stock. AB shareholders would receive $38 per share in cash and stock, representing a 17 percent premium over the share’s closing price on Wednesday, June 11, 2008.Starting at €5.74